| 胰升血糖素样肽-1受体激动剂在2型糖尿病合并心血管疾病管理中的作用 |
| |
| 引用本文： | 李强,郭琳. 胰升血糖素样肽-1受体激动剂在2型糖尿病合并心血管疾病管理中的作用[J]. 中华糖尿病杂志, 2014, 22(11): 1051-1053 |
| |
| 作者姓名： | 李强 郭琳 |
| |
| 作者单位： | 150086,哈尔滨医科大学附属第二医院内分泌代谢病科 |
| |
| 摘 要： | T2DM患者常合并多重心血管危险因素,如血脂异常、高血压以及治疗过程中常伴发的低血糖、体重增加等.因此,T2DM患者是心血管疾病的高危人群.为降低T2DM的心血管风险,应控制血糖、血压、血脂、体重等指标.胰升血糖素样肽-1（GLP-1）受体激动剂在动物、细胞研究及临床试验中均显示具有心血管保护作用,可用于T2DM合并心血管疾病的管理.
|
| 关 键 词： | 糖尿病,2型 心血管疾病 胰升血糖素样肽-1 胰升血糖素样肽-1受体激动剂 |
Management of type 2 diabetes combined with cardiovascular diseases |
| |
| LI Qiang,GUO Lin. Management of type 2 diabetes combined with cardiovascular diseases[J]. CHINESE JOURNAL OF DIABETES MELLITUS, 2014, 22(11): 1051-1053 |
| |
| Authors: | LI Qiang GUO Lin |
| |
| Affiliation: | ( Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China) |
| |
| Abstract: | Type 2 diabetes is often combined with multiple risk factors for cardiovascular disease, such as dyslipidaemia, hypertension, hypoglycaemia and weight gain induced by anti diabetic drugs. Patients with type 2 diabetes are at high risk for cardiovascular diseases. To minimize the risk for cardiovascular disease, comprehensive management on hyperglycaemia, hypertension, dyslipidaemia and overweight/obesity is essential. Recent studies had revealed the beneficial effects of GLP-1 on cardiovascular system. |
| |
| Keywords: | Diabetes mellitus,type 2 Cardiovascular diseases Glucagon-like peptide-1 (GLP-1) Glucagon-like peptide-1 (GLP-1) receptor agonists |
| 本文献已被 维普 等数据库收录！ |
|
